- CMTA Appoints Biotech Industry Veteran Suzanne Bruhn, PhD as New CEO
GLENOLDEN, Pa., November 6, 2023 – The Charcot-Marie-Tooth Association announced Nov. 6 that Suzanne (Sue) Bruhn, PhD, an accomplished biotech executive with extensive experience in the development and commercialization of treatments for rare diseases, will take the helm of the ...Read more ... - October 2023 Community Statement from Novartis“The CMTA welcomes this community update from Novartis and applauds its leading role in the development of treatments for CMT. The CMTA has been maintaining regular contact, providing support and feedback to Novartis during this early transition and integration phase. ...Read more ...
- CMTA Awards $225,483 for Study On Using ASOs to Treat CMT2EThe Charcot-Marie-Tooth Association (CMTA) Board of Directors announced Sept. 28 that it has approved a $225,483 award to Dr. Mario Saporta at the University of Miami for a study on the use of antisense oligonucleotides (ASOs) to treat CMT2E. CMT is ...Read more ...
- Understanding Charcot-Marie-Tooth Disease in ChildrenThis CMT awareness month, the CMTA’s Chief Research Officer, Katherine Forsey, PhD, shares her perspective as a CMT mum and how she navigated her own child’s participation in CMT research. Charcot-Marie-Tooth disease (CMT) affects the peripheral nerves; the nerves that ...Read more ...
- Muscular Dystrophy Association and Charcot-Marie-Tooth Association Announce Collaborative Non-Viral Gene Therapy Research GrantNew York, NY – September 12, 2023 — The Muscular Dystrophy Association (MDA) and Charcot-Marie-Tooth Association (CMTA) today announced a collaborative research grant totaling $299,992 to test gene delivery to Schwann cells using nanoparticles to treat CMT1X. The three-year study, ...Read more ...
Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
